|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
The
expression of CD154 (CD40 ligand), a member of the Tumor Necrosis Factor gene
family, by activated T lymphocytes is critical in the development of humoral
and cell-mediated immunity. CD154 blockade retards the development and
progression of immune responses in an array of transplantation and autoimmune
disease models ranging from Systemic Lupus Erythematosus to Rheumatoid
Arthritis to Multiple Sclerosis. Overexpression of splice isoforms of
polypyrimidine tract binding protein differentially regulate CD154 expression
and mRNA accumulation in a 3'-UTR-dependent manner in cell lines and normal
human T cells. This
technology is claimed in the published United States Patent Application Nos. 11/854,148
and 12/064,471. We are seeking an industrial partner interested in its
commercialization. (Ref.: J323) |
||
|
|
|
|
|
|
|
|
«Technology Transfer Office : Sponsored Projects : Dartmouth College |
|||
|
|
||||
|
|
||||
|
|
Phone: (603) 646-3027 |
|||
|
|
|
|
Fax: (603) 646-3670 |
|